Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05142033 · ClinicalTrials.gov registry record
Avera Cancer Sequencing and Analytics Protocol (ASAP)
A clinical trial of Breast Cancer and Cancer, sponsored by Avera McKennan Hospital & University Health Center.
- Recruiting
- Registry status
- 25,000
- Enrollment target
- 2
- Study locations
NCT05142033 is a study of Breast Cancer and Cancer that is actively recruiting participants, run by Avera McKennan Hospital & University Health Center. The registered enrollment target is 25,000 participants, above the 2,783-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (798% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT05142033, a study of Breast Cancer and Cancer, is actively recruiting participants, sponsored by Avera McKennan Hospital & University Health Center.
- RECRUITING
- Registry status
- 25,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand the breadth of molecular characteristics present in participants cared for in a large integrated, community-based health care system. Using comprehensive genomic profiling and proteomics, the investigators seek to identify the underlying genomic drivers of premalignant or malignant conditions in participants across different stages of disease development and cancer types. Comprehensive molecular profiling will consist of somatic tumor testing (tissue and/or blood) using whole exome sequencing, whole transcriptome sequencing, proteomics, and selected instances of whole genome sequencing. In addition, the investigators seek to perform broad hereditary cancer testing in affected participant populations. Hereditary testing has implications in screening, prognosis, and therapeutics for affected participants, as well as broad implications for genetic counseling and cascade testing. In order to maximize the value of genomic information, participants consented to this protocol will have their electronic health records (both retrospectively and prospectively) abstracted, curated, annotated and linked to genomic information obtained though the testing performed. Given the long-term value of this data, participants will also be asked to voluntarily consent to have their samples stored in a biobank and have their de-identified information used for future research. Information collected across this participant population will aid in advancing the investigators' knowledge of cancer biology, to discover and validate biomarkers associated with clinical outcomes, and shared in collaborative projects in order to promote the study of cancer.
Conditions Studied
Study Locations (2)
South Dakota
- Avera Cancer Institute - Aberdeen - Aberdeen
- Avera Cancer Institute - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,000 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05142033
The ClinicalTrials.gov registry entry for NCT05142033 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,783-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (798% higher). The listed sponsor is Avera McKennan Hospital & University Health Center, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05142033 reports 2 study locations spanning 1 distinct geographic area - top geographies include South Dakota.
Frequently Asked Questions
What is clinical trial NCT05142033 about?
NCT05142033 is a clinical study titled "Avera Cancer Sequencing and Analytics Protocol (ASAP)". The purpose of this study is to understand the breadth of molecular characteristics present in participants cared for in a large integrated, community-based health care system. Using comprehensive genomic profiling and proteomics, the investigators seek to identify the underlying genomic drivers of ...
What is the current status of trial NCT05142033?
This trial is currently recruiting. The enrollment target is 25,000 participants. The study started on 2021-11-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05142033 study?
This clinical trial studies the following conditions: Breast Cancer, Cancer, Lung Cancer, Ovarian Cancer, Endometrial Cancer.
Who is sponsoring clinical trial NCT05142033?
This trial is sponsored by Avera McKennan Hospital & University Health Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05142033 being conducted?
This trial has 2 study locations across South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.